Pure autonomic failure (PAF) is a rare neurodegenerative condition in which the body’s autonomic nervous system progressively breaks down, leaving a person unable to regulate blood pressure, sweating, bladder function, and other processes that normally run on autopilot. The hallmark problem is orthostatic hypotension, a dramatic drop in blood pressure upon standing that can cause dizziness, lightheadedness, or fainting.1PubMed Central. Pure Autonomic Failure PAF typically surfaces in middle age or later, and while it progresses slowly compared with related disorders, it carries a meaningful risk of evolving into a broader neurological disease over time.
What PAF Feels Like Day to Day
The most disabling symptom for most people with PAF is orthostatic hypotension. Standing up from a chair or getting out of bed can trigger a sudden blood-pressure plunge, leading to blurred vision, wooziness, neck and shoulder pain (sometimes called “coat-hanger” pain because it follows the trapezius muscles), or outright fainting. Episodes tend to be worse in the morning, after meals, and in warm environments, all situations that naturally shift blood toward the legs or the gut.
But PAF rarely stops at blood pressure. A large study evaluating the full symptom profile found that about 59% of patients had bladder problems, ranging from urgency to full incontinence or the need for catheterization. Constipation affected roughly 45%, sexual dysfunction about 40%, and problems with body-temperature regulation around 38%.2PubMed Central. The phenotype of “pure” autonomic failure Widespread loss of sweating, called anhidrosis, is another common complaint; some people notice they simply cannot cool down during exercise or in hot weather. Autonomic testing in that same study showed a median loss of sweating over about half the body surface, underscoring how extensive the nerve damage can become.2PubMed Central. The phenotype of “pure” autonomic failure
Quality-of-life surveys paint a sobering picture. Physical health scores in PAF patients are significantly lower than in the general population, and about half of participants show at least mild dependence on others for daily activities. Urinary control tends to be the single most impaired function. Interestingly, how long someone has had PAF and whether they have depression are less strongly linked to physical health scores than the severity of their autonomic symptoms themselves, and personal resilience appears to buffer the relationship between symptom burden and disability.3PubMed. Quality of life and disability in pure autonomic failure: More than a prodromal synucleinopathy
Why It Happens
PAF belongs to a family of diseases called alpha-synucleinopathies, conditions united by the abnormal buildup of a protein called alpha-synuclein. Parkinson’s disease, dementia with Lewy bodies (DLB), and multiple system atrophy (MSA) are the better-known members of this family. What sets PAF apart is where the protein accumulates: predominantly in autonomic nerve ganglia and peripheral autonomic nerve fibers, rather than deep inside the brain.4PubMed Central. Pure Autonomic Failure-A Localized Alpha Synucleinopathy with a Potential for Conversion to More Extensive Alpha Synucleinopathies
Because the damage is concentrated in peripheral nerves that carry signals out from autonomic ganglia, the pattern of failure is “postganglionic.” The sympathetic nerve endings that are supposed to release norepinephrine to tighten blood vessels, stimulate sweat glands, and keep the heart responsive are destroyed or dysfunctional. Without adequate norepinephrine release, blood vessels cannot constrict when you stand, blood pools in the legs, and blood pressure plummets. The same nerve loss explains the anhidrosis: sweat glands lose their nerve supply. Skin biopsies from PAF patients show a visible loss of both noradrenergic and cholinergic autonomic nerve fibers.5Mayo Clinic Proceedings. Pure Autonomic Failure – Section: Pathophysiology
No one knows exactly why alpha-synuclein starts misfolding in PAF, and there are no established genetic mutations or environmental triggers specific to the condition. The cause remains one of the biggest open questions in the field.
How PAF Is Diagnosed
PAF does not have a single definitive blood test or brain scan, so diagnosis rests on a combination of clinical history, autonomic function testing, and ruling out other causes of orthostatic hypotension. Doctors look for a sustained drop in systolic blood pressure of at least 20 mmHg (or diastolic of at least 10 mmHg) within three minutes of standing, along with symptoms of autonomic failure across multiple organ systems, and no evidence of a central neurological disease like Parkinson’s or MSA.
Formal autonomic testing often includes a tilt-table exam, thermoregulatory sweat testing (which maps the areas of the body that have lost the ability to sweat), and cardiovagal reflex testing. These help confirm the pattern of postganglionic failure. One tricky point: plasma norepinephrine levels, which are often low in PAF because of peripheral nerve loss, can be misleading during a tilt test. A study found that even though norepinephrine concentrations appeared to rise during tilt in PAF patients, the increase was entirely explained by a reduction in how fast the body clears norepinephrine from the bloodstream, not by actual nerve release.6PubMed. Plasma norepinephrine responses to head-up tilt are misleading in autonomic failure Relying on that test alone could produce a false reassurance.
Skin Biopsy for Alpha-Synuclein
A more recent and increasingly validated approach is skin biopsy looking for phosphorylated alpha-synuclein (P-SYN) deposited in nerve fibers. A large multicenter study found P-SYN in 100% of confirmed PAF cases (22 out of 22), compared with only about 3% of healthy controls. The same test also picked up Parkinson’s disease at about 93%, MSA at 98%, and DLB at 96%, which makes it broadly useful for confirming a synucleinopathy rather than pinpointing PAF specifically.7JAMA. Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies An earlier, smaller study noted that the pattern of alpha-synuclein deposits in the skin differs between PAF and Parkinson’s: in PAF, abnormal deposits appeared at every biopsy site tested, while in Parkinson’s only about half of skin samples were positive, with a preference for proximal body sites.8PubMed. Skin nerve misfolded α-synuclein in pure autonomic failure and Parkinson disease That distribution pattern could eventually help clinicians distinguish the two conditions early on.
Cardiac Imaging
MIBG scintigraphy, a nuclear-medicine scan that measures how well the heart’s sympathetic nerves take up a radioactive tracer, is another useful tool. A systematic review found abnormal MIBG uptake in about 85% of PAF patients, reflecting the cardiac sympathetic denervation that is characteristic of the disease.9PubMed. Cardiac MIBG scintigraphy in pure autonomic failure: A systematic review The heart-to-mediastinum uptake ratio is significantly lower in PAF (as well as in Parkinson’s and DLB) compared with MSA, where cardiac nerves are relatively spared. This distinction makes MIBG imaging particularly helpful for telling PAF apart from MSA.10Journal of Nuclear Medicine. Reduced Cardiac Uptake and Enhanced Washout of 123I-MIBG in Pure Autonomic Failure Occurs Conjointly with Parkinson’s Disease and Dementia with Lewy Bodies
Telling PAF Apart from Multiple System Atrophy
The distinction between PAF and MSA matters enormously for prognosis. PAF tends to progress slowly, and many patients remain functionally stable for years. MSA, by contrast, involves progressive cerebellar or parkinsonian motor symptoms on top of autonomic failure, and life expectancy after diagnosis is considerably shorter. Yet in the early stages, both conditions can look alike: an otherwise healthy-seeming adult who develops severe orthostatic hypotension and bladder trouble.
The clinical course itself offers clues. In PAF, fainting and sweating problems tend to appear first, followed by constipation and syncope, with urinary dysfunction coming later. In MSA, urinary problems usually appear early and respiratory dysfunction eventually follows, a pattern almost never seen in PAF.11Journal of Neurology, Neurosurgery & Psychiatry. Progression and prognosis in pure autonomic failure (PAF): comparison with multiple system atrophy Skin vasomotor reflex testing can also help: PAF patients show a diminished skin blood-vessel response to stimuli like a cold stimulus or a gasp, consistent with postganglionic nerve destruction, whereas MSA patients preserve that response because their peripheral nerves are intact and the damage is more central.12PubMed. Skin vasomotor reflex responses in two contrasting groups of autonomic failure: multiple system atrophy and pure autonomic failure Similarly, sweat reflex testing tends to show a different pattern: MSA patients preserve skin vasomotor responses but lose sweat responses, while PAF patients lose both.13Parkinsonism & Related Disorders. Differences in skin sympathetic involvements between two chronic autonomic disorders: Multiple system atrophy and pure autonomic failure
The Risk of Phenoconversion
One of the most important things anyone with PAF needs to understand is that the diagnosis does not always stay “pure.” Because PAF shares its underlying biology with Parkinson’s, DLB, and MSA, a fraction of PAF patients will eventually develop one of these broader diseases, a process researchers call phenoconversion. A prospective U.S. cohort study found that within four years of follow-up, about 34% of PAF patients had evolved into a central nervous system synucleinopathy: DLB in roughly half of converters, Parkinson’s disease in about a quarter, and MSA in another quarter.14PubMed Central. Natural history of pure autonomic failure: A United States prospective cohort
Certain features raise the odds. REM sleep behavior disorder (RBD), a condition in which people physically act out their dreams by kicking, punching, or calling out during sleep, was strongly associated with later conversion, carrying about seven times the odds of developing a central synucleinopathy.14PubMed Central. Natural history of pure autonomic failure: A United States prospective cohort RBD is common in PAF. A small case series using formal sleep-lab testing confirmed it in 63% of PAF patients evaluated, suggesting brainstem involvement even in a condition labeled “pure” autonomic failure.15PubMed. A case series of REM sleep behavior disorder in pure autonomic failure A larger phenotype study found that over half of patients who were screened endorsed dream enactment behavior, with a median onset about seven years after orthostatic hypotension appeared.2PubMed Central. The phenotype of “pure” autonomic failure
Researchers have identified separate predictive profiles depending on which disease PAF converts to. Patients who go on to develop MSA tend to be younger at onset, have severe bladder and bowel problems, preserve their sense of smell, have supine norepinephrine levels above 100 pg/mL, and show a heart rate increase of more than 10 beats per minute on tilt. Those who convert to Parkinson’s or DLB tend to have reduced sense of smell, a smaller heart-rate response to tilt, and a longer duration of illness before conversion.16PubMed Central. Pure autonomic failure: Predictors of conversion to clinical CNS involvement These predictive variables are not yet used in routine clinical scoring, but they are actively being refined into composite risk tools.
Drug Treatment for Orthostatic Hypotension
No medication cures PAF or halts the underlying nerve loss. The pharmacological goal is to keep blood pressure high enough when standing that a person can get through daily life safely. Several drugs are used, each working through a different mechanism:
- Midodrine: A direct-acting alpha-1 agonist that tightens blood vessels. It raises both resting and standing blood pressure and speeds blood-pressure recovery after exercise.17PubMed. Effects of midodrine on exercise-induced hypotension and blood pressure recovery in autonomic failure It is one of the most widely prescribed drugs for orthostatic hypotension, though it can worsen supine hypertension.
- Droxidopa: A synthetic amino acid that the body converts into norepinephrine, effectively replacing the neurotransmitter that damaged nerves can no longer produce.18Expert Review of Cardiovascular Therapy. Droxidopa in neurogenic orthostatic hypotension It works best in patients whose supine norepinephrine levels are low. A study found that a supine norepinephrine level below about 220 pg/mL predicted a good blood-pressure response to droxidopa with high sensitivity and specificity.19PubMed Central. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension
- Atomoxetine: Originally a norepinephrine reuptake inhibitor used for attention-deficit disorder, atomoxetine blocks the reabsorption of whatever norepinephrine the remaining nerves still release. In a head-to-head trial of 65 patients with autonomic failure, atomoxetine produced a greater increase in standing blood pressure than midodrine and also improved orthostatic symptoms relative to placebo, while midodrine did not reach statistical significance on the symptom measure.20PubMed Central. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure This makes atomoxetine an appealing option, though it requires that the patient still have some residual norepinephrine-releasing nerve fibers.
- Fludrocortisone: A synthetic mineralocorticoid that increases blood volume by promoting salt and water retention.21PubMed Central. Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms It does not directly fix nerve damage but offsets the consequences by keeping more fluid in the circulatory system.
- Pyridostigmine: A cholinesterase inhibitor that enhances nerve-to-nerve signaling in autonomic ganglia, secondarily boosting blood pressure.21PubMed Central. Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms Its blood-pressure effect is modest, and it is sometimes used as an add-on rather than a standalone treatment.
In practice, doctors often combine agents and adjust doses over time as the disease progresses. A patient with very low norepinephrine levels may respond well to droxidopa, whereas someone with some residual nerve function may do better with atomoxetine. This is one area where a supine norepinephrine measurement has clear practical value, going beyond diagnosis and into treatment selection.
The Supine Hypertension Paradox
One of the most frustrating aspects of managing PAF is that roughly half of patients who cannot maintain their blood pressure upright develop dangerously high blood pressure while lying down.22PubMed Central. Diagnosis and treatment of supine hypertension in autonomic failure patients with orthostatic hypotension The mechanism is not fully understood. In MSA, residual sympathetic tone is thought to drive the hypertension, but in PAF, norepinephrine and renin levels are both very low, and yet blood-vessel resistance rises anyway. The hypertension is not just a nuisance: it causes pressure-driven fluid loss through the kidneys at night, which worsens orthostatic hypotension the next morning. Over time, it can lead to thickening of the heart wall.
Managing this seesaw is tricky because anything that raises standing blood pressure risks pushing supine blood pressure even higher. The first-line approach is positional: avoid lying flat during the day, and sleep with the head of the bed elevated.23PubMed Central. Management approaches to hypertension in autonomic failure Short-acting blood-pressure-lowering medications like nitroglycerin patches applied at bedtime can help during the night without carrying over into the next morning.22PubMed Central. Diagnosis and treatment of supine hypertension in autonomic failure patients with orthostatic hypotension No current antihypertensive used in this setting has been shown to actually improve morning orthostatic tolerance, though, so treatment remains a balancing act rather than a true fix.
Non-Drug Strategies That Help
Lifestyle adjustments are not optional extras in PAF; they form the backbone of daily management. Increasing salt and fluid intake expands blood volume, which partially compensates for poor vascular constriction. Compression garments, particularly abdominal binders and thigh-high stockings, reduce venous pooling. Standing up slowly and in stages, crossing the legs while standing, and squatting when dizziness hits are simple physical countermaneuvers that buy time for the cardiovascular system to catch up.
Water drinking has a surprisingly specific benefit. A study in PAF patients found that drinking water did not change the abnormal blood-pressure responses during supine exercise, but it did improve orthostatic tolerance after exercise, meaning patients were less likely to become lightheaded when standing up afterward.24PubMed. Effects of water drinking on cardiovascular responses to supine exercise and on orthostatic hypotension after exercise in pure autonomic failure Drinking a glass or two of water about 15 to 30 minutes before activities that involve standing can be a practical buffer.
Timing matters as well. Blood pressure in PAF tends to be lowest in the morning and after meals. Eating smaller, more frequent meals reduces postprandial blood pooling in the gut. Many patients learn to schedule physically demanding tasks for the afternoon, when blood pressure is somewhat more stable, and to avoid hot showers or baths that dilate skin blood vessels.
REM Sleep Behavior Disorder and What It Signals
Violent or vivid dream enactment during sleep is more than a curiosity in PAF. RBD involves loss of the normal muscle paralysis that keeps people still during dreaming sleep, and its presence implies that the disease process has reached the brainstem, a region that should be spared in “pure” autonomic failure. The fact that a majority of carefully tested PAF patients have polysomnography-confirmed RBD challenges the assumption that the disease is entirely peripheral.15PubMed. A case series of REM sleep behavior disorder in pure autonomic failure
From a practical standpoint, RBD is the strongest known predictor of eventual phenoconversion to a central synucleinopathy. Bed partners of PAF patients often notice the dream-enactment behavior before the patient does. Reporting it to a physician prompts closer surveillance for early signs of Parkinson’s, DLB, or MSA, potentially allowing earlier intervention. For the patient, knowing about this connection is empowering rather than alarming: it shifts the monitoring strategy from waiting for obvious motor symptoms to proactively screening for cognitive, olfactory, and motor changes at regular intervals.
Why the Name “Pure” Is Contested
The word “pure” in pure autonomic failure was meant to distinguish it from autonomic failure that comes packaged with obvious motor or cognitive disease. But the evidence paints a more complicated picture. Many patients have brainstem involvement (shown by RBD), some develop subtle cognitive changes, and up to a third eventually convert to a more widespread synucleinopathy. The large phenotype study found that autonomic testing showed moderate to severe autonomic failure in most patients, with sweating loss and bladder dysfunction reaching levels that substantially affect independence.2PubMed Central. The phenotype of “pure” autonomic failure Meanwhile, quality-of-life data show that the condition’s impact on daily functioning rivals that of many “less pure” neurological diseases.3PubMed. Quality of life and disability in pure autonomic failure: More than a prodromal synucleinopathy
Some researchers now view PAF less as a stable, benign end point and more as a stage within a continuum of synucleinopathy that may or may not spread centrally over time. That reframing has clinical consequences: it argues for ongoing monitoring even in patients who seem stable, and it positions PAF as a potential early window in which future disease-modifying therapies, if any emerge, might halt the spread of alpha-synuclein before it reaches the brain. For now, that remains a research aspiration rather than a clinical reality, but it is one reason PAF has drawn increasing interest from neurologists studying synucleinopathies broadly.